Seema Verma, the nominee to head the Centers for Medicare & Medicaid, said at her confirmation hearing that she would like to review the way pharmaceutical companies classify products as generic or branded, citing the case of Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device.
Mylan faced criticism this year for classifying EpiPen as a generic and paying smaller rebates to Medicaid than if the device was listed as branded.
Get the full story at our sister site, Drug Delivery Business News.
The post CMS nominee Verma: Mylan’s EpiPen case ‘disturbing’ appeared first on MassDevice.